title: Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma.
abstract: A 5-year-old boy with glioblastoma relapsed soon after postoperative irradiation in combination with temozolomide. Second-line chemotherapy was also ineffective; therefore, the bevacizumab and irinotecan were given after a third gross-total resection of the tumor. Treatment was interrupted for 1 month due to development of posterior reversible encephalopathy syndrome, but was re-initiated at a lower dose of bevacizumab with prolonged intervals between treatments. The patient was alive and disease free 2 years after initial diagnosis. Bevacizumab and irinotecan are a promising regimen for pediatric cases of recurrent glioblastoma after gross-total resection, although the optimal treatment schedule must be determined on a patient-by-patient basis.
authors.affiliation: Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
authors.forename: Katsutsugu
authors.initials: K
authors.lastname: Umeda
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Shibata
authors.forename: Satoshi
authors.initials: S
authors.lastname: Saida
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Hiramatsu
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Arakawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Mizowaki
authors.forename: Ritsuo
authors.initials: R
authors.lastname: Nishiuchi
authors.forename: Souichi
authors.initials: S
authors.lastname: Adachi
authors.forename: Toshio
authors.initials: T
authors.lastname: Heike
authors.forename: Ken-Ichiro
authors.initials: K
authors.lastname: Watanabe
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000077146:Irinotecan; D008279:Magnetic Resonance Imaging; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011355:Prodrugs; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic; D011355:Prodrugs; D000068258:Bevacizumab; D000077146:Irinotecan; D002166:Camptothecin
keywords: bevacizumab; glioblastoma; irinotecan; posterior reversible encephalopathy syndrome